UCB SA (OTCMKTS:UCBJF – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $277.4375, but opened at $290.59. UCB shares last traded at $290.59, with a volume of 49 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler reiterated a “neutral” rating on shares of UCB in a report on Wednesday. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, UCB currently has an average rating of “Moderate Buy”.
Read Our Latest Analysis on UCB
UCB Price Performance
About UCB
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.
Further Reading
- Five stocks we like better than UCB
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
